Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

NCT06084689 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Discontinuation of molecule development

Conditions

Interventions

Sponsor

Institut Bergonié

Collaborators